Clicky

NeuroBo Pharmaceuticals, Inc.(NRBO) News

Date Title
Jul 30 NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01
Jun 26 NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Jun 25 NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Jun 24 NeuroBo Pharmaceuticals Announces Private Placement, Registered Direct Offering
Jun 24 NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Jun 22 NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models
May 9 NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Apr 30 NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June
Apr 23 NRBO: First Patient Dosed in Phase 1 Trial of DA-1726 for the Treatment of Obesity…
Apr 17 NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Apr 1 NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
Mar 28 NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
Mar 13 NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
Mar 4 NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer
Feb 29 NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Jan 9 NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement
Jan 2 NeuroBo to Participate in Industry and Investor Conferences in January
Dec 28 NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
Dec 19 NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split
Dec 1 NeuroBo to Participate in Investor Conferences in December